🇺🇸 L-leucovorin in United States
106 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 106
Most-reported reactions
- Non-Hodgkin^S Lymphoma Recurrent — 27 reports (25.47%)
- Disease Progression — 15 reports (14.15%)
- Neutropenia — 13 reports (12.26%)
- Diarrhoea — 9 reports (8.49%)
- Anaemia — 7 reports (6.6%)
- Decreased Appetite — 7 reports (6.6%)
- Fatigue — 7 reports (6.6%)
- Leukopenia — 7 reports (6.6%)
- Nausea — 7 reports (6.6%)
- Stomatitis — 7 reports (6.6%)
Other Oncology approved in United States
Frequently asked questions
Is L-leucovorin approved in United States?
L-leucovorin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for L-leucovorin in United States?
Gruppo Oncologico del Nord-Ovest is the originator. The local marketing authorisation holder may differ — check the official source linked above.